^
Association details:
Biomarker:No biomarker
Cancer:Mantle Cell Lymphoma
Regimen:R-DHAX (cytarabine + dexamethasone injection + oxaliplatin + Rituxan (rituximab)) R-CHOP (cyclophosphamide + doxorubicin hydrochloride + + Rituxan (rituximab) + vincristine)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
05/11/2023
Excerpt:
Mantle Cell Lymphoma….Preferred regimens...LyMA regimen: RDHA (rituximab, dexamethasone, cytarabine) + platinum (carboplatin, cisplatin, or oxaliplatin) x 4 cycles followed by RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) for non-PET CR. TRIANGLE regimen: Alternating RCHOP + covalent BTKig/RDHA (rituximab, dexamethasone, cytarabine) + platinum (carboplatin, cisplatin, or oxaliplatin).